Skip to content

Neuroplasticity: all studies

Page 101 of 178: studies 1,001 to 1,010 of 1,772, newest first. Back to the neuroplasticity overview

Research

Ketamine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

July 11, 2025 Sebastián Malleza

After completing this activity, participants should be able to: Analyze the pharmacodynamic mechanisms of ketamine, including its primary action as an NMDA receptor antagonist and secondary effects on AMPA receptors, opioid systems, and neuroplasticity pathways, to optimize treatment selection for patients with treatment-resistant depression. Evaluate clinical scenarios to determine when...

Ketamine-gids: farmacologie, indicaties, doseringsrichtlijnen en bijwerkingen

July 11, 2025 Sebastián Malleza

Na het voltooien van deze activiteit moeten deelnemers in staat zijn om: De farmacodynamische mechanismen van ketamine te analyseren, inclusief de primaire werking als NMDA-receptorantagonist en secundaire effecten op AMPA-receptoren, opioïde systemen en neuroplasticiteitspathways, om de behandelkeuze voor patiënten met therapieresistente depressie te optimaliseren. Klinische scenario's te...

Females in Psychedelic Research: A Perspective for Advancing Research and Practice.

ACS Pharmacology & Translational Science July 11, 2025 Zahira Ziva Cohen, Grace Blest‐hopley 9 citations

The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current psychedelic research and clinical protocols. Traditional practices and case studies underscore the importance of accounting for these factors in investigations of psychedelic effects. This opinion paper explores the critical intersections between...

Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.

CNS Drugs July 10, 2025 Eric A. Miller, Christy Capone, Erica Eaton et al. 4 citations

Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lysergic acid diethylamide (LSD), and several contemporary trials of psilocybin and ayahuasca for this indication. Herein, we characterize foundational studies from the 1950s to the present, with emphasis on key design factors that varied considerably...

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.

ACS Chemical Neuroscience July 9, 2025 Xue Wang, Fan Jun, Cong Lin et al. 4 citations

Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and microbial metabolism. This viewpoint highlights how psychedelics may reshape microbiota and how microbes influence psychedelic efficacy, proposing microbiome-informed strategies─such as probiotics or dietary interventions─to personalize and enhance...

Syner-G: Antidepressant action of psychedelics at the glutamatergic interface of brain, behavior and the immune system

July 3, 2025 Natasha L. Mason, Pablo-Alexandre Mallaroni, Attila Szabo et al. preprint

Promising results have emerged in the use of psychedelic drugs for treating depression. Despite multiple neural models attempting to elucidate the acute psychedelic experience, and an increased focus on potential mechanisms driving persistent change, the connections between the acute state and the enduring therapeutic outcomes remain elusive. This targeted review aims to bridge this gap by...

DOI: 10.31234/osf.io/g49mp_v1 (opens in new tab) Glutamatergic Action physics Antidepressant Immune system +3

An Update on the Behavioral and Neurobiological Effects of Cannabis Use in Adolescents: A Translational Perspective.

American Journal of Psychiatry July 1, 2025 Y. Hurd

The convergence of early initiation, increasing product potency, and widespread availability has reshaped the contemporary cannabis landscape, heightening concerns about its impact on adolescent mental health. Translational research combining longitudinal human neuroimaging and animal models provides compelling evidence that cannabis use-particularly with high-tetrahydrocannabinol (THC)...

Astrogliosis Occurs Selectively in Amygdala of Adolescent Primate and Rodent Following Daily Δ9-Tetrahydrocannabinol, Prevented by Cannabidiol Co-Treatment.

Biological Psychiatry Global Open Science July 1, 2025 Yalin Sun, Meenalochani Sivasubramanian, Marija Milenkovic et al.

Adolescent-onset cannabis use confers higher risk for neuropsychiatric disorders, implicating amygdala dysfunction. However, the mechanisms that mediate Δ9-tetrahydrocannabinol (THC)-triggered neuroadaptive changes in the maturing amygdala remain unclear. Proteomic analysis of amygdala tissue from male adolescent Saimiri boliviensis nonhuman primates chronically treated with THC provided leads...

Assessment of complement cascade components in patients with major depressive disorder.

Brain, Behavior, and Immunity July 1, 2025 Brandi Quintanilla, Dede Greenstein, Ashutosh Tripathi et al. 7 citations

Recent evidence suggests that the rapid-acting antidepressant ketamine has immune regulatory functions. The complement system is an important component of the innate immune response and plays a key role in synaptic plasticity. An increase in complement component 3 (C3) expression was previously found in the prefrontal cortex of individuals with depression. Given the complement system's role in...

DOI: 10.1016/j.bbi.2025.03.009 (opens in new tab) Full text (opens in new tab) Depressive disorder Immune function Antidepressant Depression major depression +6

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine